Hepsera Related Published Studies
Well-designed clinical trials related to Hepsera (Adefovir Dipivoxil)
HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy. [2009.05]
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. [2009.03]
Complex dynamics of hepatitis B virus resistance to adefovir. [2009.01]
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. [2008.12.04]
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. [2008.11]
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. [2008.09]
The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. [2008.04]
Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. [2008]
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. [2007.12.04]
Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. [2007.12]
Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. [2007.11.15]
Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis with Telbivudine or Adefovir: A Randomized Trial. [2007.10.01]
[Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: A randomized, double-blind, multicenter clinical study.] [2007.09]
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. [2007.02]
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. [2006.12]
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. [2006.11]
[A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B] [2006.11]
A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. [2006.07]
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. [2005.06.30]
Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. [2004.09]
Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. [2004.01]
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. [2004.01]
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. [2004.01]
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. [2003.07]
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. [2003.07]
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. [2003.02.27]
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. [2003.02.27]
The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. [2001.09.07]
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. [2001.08.15]
Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. [1999.12.22]
A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. [1999.09]
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. [1998.07]
The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. [1997.12]
Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. [1997.08]
Well-designed clinical trials possibly related to Hepsera (Adefovir Dipivoxil)
Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. [2005.10.07]
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. [2003.01]
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. [2002.07.10]
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884. [2000.11.10]
Other research related to Hepsera (Adefovir Dipivoxil)
Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg chronic hepatitis B patients: A 4-year study. [2009.09.22]
Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. [2009.09]
Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. [2009.07]
Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis. [2009.05]
Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy. [2009.04]
A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. [2009.04]
[Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients] [2009.03]
Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. [2009]
Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. [2009]
Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. [2009]
Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients. [2009]
Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. [2009]
[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection] [2008.12]
Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. [2008.11.15]
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. [2008.10.22]
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. [2008.10]
[A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus] [2008.09]
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. [2008.07.21]
Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. [2008.07]
Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. [2008.06]
Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy. [2008.06]
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. [2008.05]
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. [2008.05]
Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. [2008.04]
Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B. [2008.03.21]
[Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients] [2008.03]
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. [2008.02.29]
Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. [2008.02.14]
Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. [2008.02.01]
Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. [2008.02]
Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. [2008.01]
Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. [2008]
Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil. [2008]
Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. [2008]
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. [2007.12.31]
Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. [2007.12]
Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. [2007.11.15]
[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period.] [2007.11]
[Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis] [2007.10.27]
Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. [2007.10]
Effects of adefovir dipivoxil therapy in asian and caucasian patients with chronic hepatitis B. [2007.09.14]
[Diammonium glycyrrhizinate does not affect efficacy of adefovir dipivoxil therapy in patients with HBeAg-positive chronic hepatitis B.] [2007.09]
Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. [2007.09]
Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. [2007.08.14]
Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. [2007.08]
Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy. [2007.07]
[Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients.] [2007.05]
Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. [2007.05]
Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. [2007.05]
Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. [2007.05]
Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. [2007.04.15]
[A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B] [2007.04]
[Recent advances in the treatment of the hepatitis HBV-related. Effectiveness and tolerability of adefovir dipivoxil] [2007.04]
[A case of chronic hepatitis B with primary adefovir resistance] [2007.04]
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. [2007.03]
A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. [2007.02]
Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection. [2007.02]
Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects. [2007.01]
Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma. [2007]
Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. [2007]
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. [2007]
A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. [2007]
[A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B.] [2006.12]
|
